Related Experiment Video
Updated: Aug 18, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous
InSug O-Sullivan1, Lauren K Ng, Don M Martinez
1Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, Illinois 60612, USA. insug@uic.edu
Abstract:
Immunotherapy of squamous cell carcinoma (SCC) at an early stage of the disease increases the likelihood of success. We report a new vaccination strategy designed to prepare SCC vaccines from microgram amounts of tumor tissue, enabling the treatment of patients with minimal residual disease. The vaccine was prepared by transfer of sheared genomic DNA-fragments (25 kb) from KLN205 cells, an SCC cell line of DBA/2 mouse origin, into syngeneic bone marrow-derived mature dendritic cells (DCs). More than 90% of the transfected DCs took up DNA from the neoplasm and transferred genes were expressed as protein. The DCs expressed CD11c, CD11b, and the costimulatory molecules CD40, CD80 and CD86, characteristic of mature DCs. Syngeneic DBA/2J mice, highly susceptible to the growth of KLN205 cells, were injected intravenously (i.v.) with the transfected DCs, followed by a subcutaneous (s.c.) injection of the tumor cells. The strong immunogenic properties of the transfected cells were indicated by the finding that the survival of the tumor-bearing mice was prolonged (P<.001), relative to that of mice in various control groups. Enzyme-linked immuno spot (ELISPOT IFN-gamma) assays revealed the activation of cell-mediated immunity directed toward the SCC in mice immunized with the transfected DCs. Two independent in vitro cytotoxicity assays indicated the presence of robust cell-mediated immunity directed toward the SCC in mice immunized with the transfected cells.
Insights
A novel vaccination strategy uses tumor DNA transferred into dendritic cells (DCs) to treat early-stage squamous cell carcinoma (SCC). This approach primes an effective immune response, prolonging survival in preclinical models.
Area of Science:
- Oncology
- Immunology
- Cancer Vaccines
Background:
- Early-stage immunotherapy offers better outcomes for squamous cell carcinoma (SCC).
- Minimal residual disease presents a challenge for effective SCC treatment.
- Developing vaccines from limited tumor tissue is crucial for early intervention.
Purpose of the Study:
- To present a novel vaccination strategy for preparing SCC vaccines from microgram tumor tissue amounts.
- To enable the treatment of patients with minimal residual SCC.
- To evaluate the immunogenicity and efficacy of this novel vaccine approach in a preclinical model.
Main Methods:
- Genomic DNA fragments (25 kb) from KLN205 SCC cells were transferred into mature bone marrow-derived dendritic cells (DCs).
- Transfected DCs expressed tumor-associated antigens and costimulatory molecules (CD40, CD80, CD86).
- Syngeneic DBA/2J mice received transfected DCs followed by KLN205 tumor cells; immune responses were assessed via ELISPOT and cytotoxicity assays.
Main Results:
- Over 90% of DCs successfully took up and expressed genes from the tumor DNA.
- Tumor-bearing mice treated with transfected DCs showed significantly prolonged survival (P<.001).
- Cell-mediated immunity against SCC was confirmed by IFN-gamma ELISPOT and in vitro cytotoxicity assays.
Conclusions:
- This novel vaccination strategy effectively prepares SCC vaccines from minimal tumor tissue.
- The approach elicits robust, tumor-specific cell-mediated immunity.
- This method holds promise for treating early-stage SCC and minimal residual disease.
